Sifting through countless of stocks in the Biotechnology industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Halozyme Therapeutics, Inc., AnaptysBio or Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how Halozyme Therapeutics, Inc., AnaptysBio and Inc. compare based on key financial metrics to determine which better meets your investment needs.

About Halozyme Therapeutics, Inc., AnaptysBio and Inc.

Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company’s products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 that facilitates subcutaneous (SC) administration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; and XYOSTED, an injection for SC administration of testosterone replacement therapy. The company also provides Herceptin (trastuzumab) under the brand name Herceptin Hylecta; and Phesgo to treat breast cancer; Mabthera SC for chronic lymphocytic leukemia treatment; Tecentriq SC for IV infusion; Ocrevus SC for multiple sclerosis; HYQVIA to treat primary immunodeficiency disorders; DARZALEX to treat amyloidosis, and smoldering and multiple myeloma; epinephrine Injection to treat allergic reactions; nivolumab and relatlimab to treat metastatic or unresectable melanoma; teriparatide injections; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. It has collaborations and licensing agreements with F. Hoffmann-La Roche, Ltd. and Hoffmann-La Roche, Inc.; Takeda Pharmaceuticals International AG and Baxalta US Inc.; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol Myers Squibb Company; argenx BVBA; ViiV Healthcare; Chugai Pharmaceutical Co., Ltd.; Acumen Pharmaceuticals, Inc.; Merus N.V.; and Skye Bioscience, Inc. The company was founded in 1998 and is headquartered in San Diego, California.

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics for autoimmune and inflammatory diseases in the United States. The company’s products include Rosnilimab, a selective pathogenic T cell deplete which completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis; ANB033, a CD122 antagonist, which is in a Phase 1b trial for celiac disease and eosinophilic esophagitis; ANB101, a BDCA2 modulator antibody which is in Phase 1a trial that specifically targets plasmacytoid dendritic cells and inhibits interferon secretion and modulates antigen presentation; dostarlimab, a PD-1 antagonist for various solid tumor indications; and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. It focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has collaborations agreement with GSK and Vanda. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.

Latest Biotechnology and Halozyme Therapeutics, Inc., AnaptysBio, Inc. Stock News

As of April 15, 2026, Halozyme Therapeutics, Inc. had a $8.1 billion market capitalization, compared to the Biotechnology median of $281.9 million. Halozyme Therapeutics, Inc.’s stock is down 0.7% in 2026, down 0.4% in the previous five trading days and up 13% in the past year.

Currently, Halozyme Therapeutics, Inc.’s price-earnings ratio is 26.6. Halozyme Therapeutics, Inc.’s trailing 12-month revenue is $1.4 billion with a 22.7% net profit margin. Year-over-year quarterly sales growth most recently was 51.6%. Analysts expect adjusted earnings to reach $8.050 per share for the current fiscal year. Halozyme Therapeutics, Inc. does not currently pay a dividend.

As of April 15, 2026, AnaptysBio, Inc. had a $2.0 billion market cap, putting it in the 54th percentile of all stocks. AnaptysBio, Inc.’s stock is up 38.4% in 2026, down 2.1% in the previous five trading days and up 295.4% in the past year.

Currently, AnaptysBio, Inc. does not have a price-earnings ratio. AnaptysBio, Inc.’s trailing 12-month revenue is $234.6 million with a -5.6% net profit margin. Year-over-year quarterly sales growth most recently was 151.0%. Analysts expect adjusted earnings to reach $-4.076 per share for the current fiscal year. AnaptysBio, Inc. does not currently pay a dividend.

How We Compare Halozyme Therapeutics, Inc., AnaptysBio and Inc. Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Halozyme Therapeutics, Inc., AnaptysBio and Inc.’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

Halozyme Therapeutics, Inc., AnaptysBio and Inc.’s Quality Grades

Company	Ticker	Quality
Halozyme Therapeutics, Inc.	HALO	A
AnaptysBio, Inc.	ANAB	A

Like the Value Grade, AAII’s A+ Investor Quality Grade comes from the percentile rank of key metrics. Specifically, the Quality Score is the percentile rank of the average of the percentile ranks of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and the F-Score.

The score is variable, meaning it can consider all eight measures or, should any of the eight measures not be valid, the remaining measures that are valid. To be assigned a Quality Score, stocks must have a valid (non-null) measure and corresponding ranking for at least four of the eight quality measures.

The Quality Score is used to assess the underlying “quality” of a particular stock. A higher-quality stock possesses traits associated with upside potential and reduced downside risk. Backtesting of the Quality Grade shows that stocks with higher grades, on average, outperformed stocks with lower grades over the period of 1998 through 2019.

Stocks receive better grades (higher scores) for having higher scores for the quality subcomponents and worse grades (lower scores) for lower scores for the subcomponents.

Halozyme Therapeutics, Inc. has a Quality Score of 93, which is Very Strong. AnaptysBio, Inc. has a Quality Score of 87, which is Very Strong.

The Quality Grade Winner: It’s a Tie!

Looking at the Quality Grade breakdown above, both Halozyme Therapeutics, Inc., AnaptysBio and Inc. have a grade of A. For investors who focus solely on a company’s overall quality, you will need to conduct further research into both companies to see if they are a good fit for your portfolio. As a good rule of thumb, you should always analyze multiple factors based on a wide range of metrics before choosing a company to invest in.

Halozyme Therapeutics, Inc., AnaptysBio and Inc.’s Momentum Grades

Company	Ticker	Momentum
Halozyme Therapeutics, Inc.	HALO	D
AnaptysBio, Inc.	ANAB	A

Momentum grades help to uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming. Momentum is based on the price change of a stock over a specified period relative to all other stocks.

Typically, AAII looks at the weighted relative strength over the trailing four quarters. The weighted four-quarter relative strength rank is the relative price change for each of the past four quarters. The most recent quarterly price change is given a weight of 40% and each of the three previous quarters are given a weighting of 20%.

Halozyme Therapeutics, Inc. has a Momentum Score of 38, which is Weak. AnaptysBio, Inc. has a Momentum Score of 94, which is Very Strong.

The Momentum Grade Winner: AnaptysBio, Inc.

As you can clearly see from the Momentum Grade breakdown above, AnaptysBio, Inc. is considered to have stronger momentum compared to Halozyme Therapeutics, Inc.. For those specifically looking for companies that have stronger momentum compared to other companies in the same industry, AnaptysBio, Inc. could be a good stock to invest in. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Halozyme Therapeutics, Inc., AnaptysBio and Inc.’s Estimate Revisions Grades

Company	Ticker	Earnings Estimate
Halozyme Therapeutics, Inc.	HALO	C
AnaptysBio, Inc.	ANAB	C

Earnings estimate revisions scores consider the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, positive surprises beget further positive surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Estimate revisions offer an indication of what analysts are thinking about the short-term prospects of a firm. Estimate revisions are based on the statistical significance of a firm’s last two quarterly earnings surprises and the percentage change in its consensus estimate for the current fiscal year over the past month and past three months.

Halozyme Therapeutics, Inc. has a Earnings Estimate Score of 44, which is Neutral. AnaptysBio, Inc. has a Earnings Estimate Score of 45, which is Neutral.

The Earnings Estimate Revisions Stock Winner: No Clear Winner

Neither Halozyme Therapeutics, Inc., AnaptysBio or Inc. has an Earnings Estimate Revisions Grade that could be considered a “winner.” Investors considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if Halozyme Therapeutics, Inc., AnaptysBio or Inc. is the better investment when it comes to estimate revisions.

Other Halozyme Therapeutics, Inc., AnaptysBio and Inc. Grades

In addition to Momentum, Quality and Estimate Revisions, A+ Investor also provides grades for Value and Growth.

Growth investing builds on the idea that stocks of companies exhibiting strong, consistent and prolonged growth outperform those of slower-growth companies. AAII measures growth through consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations.

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection. Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether Halozyme Therapeutics, Inc., AnaptysBio and Inc. pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, Halozyme Therapeutics, Inc., AnaptysBio or Inc. Stock?

Overall, Halozyme Therapeutics, Inc. stock has a Momentum Score of 38, Estimate Revisions Score of 44 and Quality Score of 93.

AnaptysBio, Inc. stock has a Momentum Score of 94, Estimate Revisions Score of 45 and Quality Score of 87.

Comparing Halozyme Therapeutics, Inc., AnaptysBio and Inc.’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.